MATUGGA – Dei Biopharma is awaiting approval of the World Health Organisation (WHO) to out it’s Molnupiravir drug, which will be the first such product to treat Covid-19 infection in the world.
DEI Biopharma has also laid out the plans for other essential newer products — including Paxlovid, Fluvoxamine, Ritonavir, Nirmatrelvir, and Rilpivirine.
The development was announced by DEI Group Managing Director Matthias Magoola during a visit of a team of experts from WHO at the Matugga based multibillion facility on Monday, March 7, 2022.
“When we get approvals, we can now actually offer treatment for Covid-19,” Magoola said.
The WHO experts are on a mission to Uganda since January 30, 2022 to provide technical support to the country in respect of the ongoing efforts to develop traditional based therapies for the treatment of Covid-19.
Do you have a story in your community or an opinion to share with us: Email us at editorial@watchdoguganda.com
